Acute Promyelocytic Leukaemia

  • Andrea Biondi
  • Anna Maria Testi
  • Brenda E. S. Gibson


Since the time of its first description (Degos 2003), Acute Promyelocytic Leukaemia (APL) has drawn the attention of clinicians and scientists for its clinical and biological features (Degos 2003). APL is notable for distinctive clinical and biological characteristics, including its particular morphological features, the presence of potentially devastating hemorrhagic syndrome that is related to disseminated intravascular coagulopathy and abnormal fibrinolysis, and finally, the sensitivity to anthracycline-containing chemotherapy (Bernard et al. 1973). The availability of differentation therapy with All-Trans Retinoic Acid (ATRA), and more recently, the discovery of the beneficial effect of arsenic trioxide (ATO), together with the molecular characterization of the t(15;17) specific translocation (Grignani et al. 1994) have produced a remarkable improvement in patient outcome in the last decade. Most patients with APL are now cured (Sanz 2006). APL is a paradigm of a malignant disease that can be treated by cell modulation, using agents that act specifically on oncogenic, molecular events. This chapter reviews its impact in children APL.


Hematopoietic Stem Cell Transplant Acute Promyelocytic Leukaemia Minimal Residual Disease White Cell Count Complete Remission Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Degos L: The history of acute promyelocytic leukaemia. Br J Haematol. 2003; 122(4):539–553.PubMedCrossRefGoogle Scholar
  2. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF: Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973: 41:489–496.PubMedGoogle Scholar
  3. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Pelicci PG: Acute promyelocytic leukemia: from genetics to treatment. Blood 1994: 83:10–25.PubMedGoogle Scholar
  4. Sanz MA: Treatment of acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2006:147–55. ReviewGoogle Scholar
  5. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005; 19(12):2025–2029. ReviewPubMedCrossRefGoogle Scholar
  6. Ribeiro RC and Rego E: Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration.Hematology Am Soc Hematol Educ Program. 2006:162–8. Review.Google Scholar
  7. Douer D. The epidemiology of acute promyelocytic leu-kaemia. Best Pract Res Clin Haematol. 2003;16:357–367.PubMedCrossRefGoogle Scholar
  8. Biondi A, Rovelli A, Cantu-Rajnoldi A, Fenu S, Basso G, Luciano A, Rondelli R, Mandelli F, Masera G, Testi AM: Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). Leukemia 1994: 8:1264–1268.PubMedGoogle Scholar
  9. Tomas JF, Fernandez-Ranada JM. About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain. Blood. 1996;88:2357– 2358.PubMedGoogle Scholar
  10. Ruiz-Arguelles GJ. Promyelocytic leukemia in Mexican Mestizos. Blood. 1997;89:348–349.PubMedGoogle Scholar
  11. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;88:377.PubMedGoogle Scholar
  12. Malta Corea A, Pacheco Espinoza C, Cantu Rajnoldi A, Conter V, Lietti G, Masera G, Sessa C, Cavalli F, Biondi A, Rovelli A: Childhood acute promyelocytic leukemia in Nicaragua. Ann Oncol 1993: 4:892–894.PubMedGoogle Scholar
  13. Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.Blood. 1999, 93(10):3167–3215. Review. No abstract available.PubMedGoogle Scholar
  14. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996; 87(3):882–886.PubMedGoogle Scholar
  15. Wells RA, Catzavelos C, Kamel-Reid S: Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997; 17(1):109–113.PubMedCrossRefGoogle Scholar
  16. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Howe K, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F, Lafage-Pochitaloff M: Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood. 2000 Aug 15;96(4):1297–1308.PubMedGoogle Scholar
  17. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 2003;17(2):71–97. Review.PubMedCrossRefGoogle Scholar
  18. Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8(9):1741–1749.PubMedCrossRefGoogle Scholar
  19. Catalano A, Dawson MA, Somana K, Opat S, Schwarer A, Campbell LJ, Iland H. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 2007 [Epub ahead of print].Google Scholar
  20. Umesono K, Murakami KK, Thompson CC, Evans RM: A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell. 1991;66(3):555–561.PubMedCrossRefGoogle Scholar
  21. Alland, L., Muhle, R., Hou, H., Jr., Potes, J., Chin, L., Schreiber-Agus, N. and DePinho, R. A.: Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 1997;387(6628):49–55.PubMedCrossRefGoogle Scholar
  22. Laherty, C. D., Yang, W. M., Sun, J. M., Davie, J. R., Seto, E. and Eisenman, R. N: Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 1997;89(3):349–356.PubMedCrossRefGoogle Scholar
  23. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K. and Rosenfeld, M. G: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 1997;387(6628):43–48.PubMedCrossRefGoogle Scholar
  24. Redner, R. L., Wang, J. and Liu, J. M.: Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999;94(2):417–428. Review. No abstract available.PubMedGoogle Scholar
  25. Tsai, S. and Collins, S. J.: A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc Natl Acad Sci U S A. 1993;90(15):7153–7157.PubMedCrossRefGoogle Scholar
  26. Collins, S. J.: Acute promyelocytic leukemia: relieving repression induces remission.Blood. 1998 Apr 15;91(8):2631–2633. Review. No abstract available.PubMedGoogle Scholar
  27. Koken, M. H., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., Szostecki, C., Calvo, F., Chomienne, C. and et al.: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.EMBO J. 1994 Mar 1;13(5):1073–1083.PubMedGoogle Scholar
  28. Nervi, C., Ferrara, F. F., Fanelli, M., Rippo, M. R., Tomassini, B., Ferrucci, P. F., Ruthardt, M., Gelmetti, V., Gambacorti-Passerini, C., Diverio, D., Grignani, F., Pelicci, P. G. and Testi, R.: Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998;92(7):2244–2251.PubMedGoogle Scholar
  29. Zhu, J., Gianni, M., Kopf, E., Honore, N., Chelbi-Alix, M., Koken, M., Quignon, F., Rochette-Egly, C. and de The, H.: Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A. 1999;96(26):14807–14812.PubMedCrossRefGoogle Scholar
  30. Liu, T. X., Zhang, J. W., Tao, J., Zhang, R. B., Zhang, Q. H., Zhao, C. J., Tong, J. H., Lanotte, M., Waxman, S., Chen, S. J., Mao, M., Hu, G. X., Zhu, L. and Chen, Z: Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood. 2000;96(4):1496–1504.PubMedGoogle Scholar
  31. Rovelli A, Biondi A, Cantu Rajnoldi A, Conter V, Giudici G, Jankovic M, Locasciulli A, Rizzari C, Romitti L, Rossi MR, et al.: Microgranular variant of acute promyelocytic leukemia in children.J Clin Oncol. 1992 Sep;10(9):1413–1418.PubMedGoogle Scholar
  32. Sainty D, Liso V, Cantu-Rajnoldi A, Head D, Mozziconacci MJ, Arnoulet C, Benattar L, Fenu S, Mancini M, Duchayne E, Mahon FX, Gutierrez N, Birg F, Biondi A, Grimwade D, Lafage-Pochitaloff M, Hagemeijer A, Flandrin G: A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Coomunity-Concerted Acion “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood. 2000 Aug 15;96(4):1287–1296.PubMedGoogle Scholar
  33. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Biondi A, Cocito MG, Del Vecchio L, Tabilio A, Avvisati G, Basso G, Lo Coco F: Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998 Sep;102(4):1035–1041.PubMedCrossRefGoogle Scholar
  34. Dyck JA, Warrell RP, Evans RM, Miller WH: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood 1995 86:862–7.PubMedGoogle Scholar
  35. Falini B, Flenghi L, Fagioli M, Coco FL, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S: Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 1997; 90:4046–4053.PubMedGoogle Scholar
  36. Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A, Levine K, Evans RM, Dmitrovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992; 89:2694–2698.PubMedCrossRefGoogle Scholar
  37. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, Lo Coco F, Diverio D, Pogliani EM, Lanzi EM, et al.: Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80:492–497.PubMedGoogle Scholar
  38. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia. 2002;16:1959–1973.PubMedCrossRefGoogle Scholar
  39. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13:1901–1928.PubMedCrossRefGoogle Scholar
  40. Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H, and Creutzig U. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Annals of Hematology 2001; 80: 417–422.PubMedCrossRefGoogle Scholar
  41. de Botton S, Coiteux V, Chevret S, Raynon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy J Clin Oncol 2004; 22:1404–1412.PubMedCrossRefGoogle Scholar
  42. Ortega JJ, Madero L, Martin G, Verdeguer A, Garcia P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodriguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, González JD, Bolufer P, González M, Sanz MA. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol 2005; 23: 7632–7640.PubMedCrossRefGoogle Scholar
  43. Testi AM, Biondi A, Lo-Coco F, Moleti ML, Giona F, Vignetti M, Menna G, Locatelli F, Pession A, Barisone E, De Rossi G, Diverio D, Micalizzi C, Aricò M, Basso G, Foa R, Mandelli F. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447–453.PubMedCrossRefGoogle Scholar
  44. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C & Degos L. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.PubMedGoogle Scholar
  45. Sanz MA, Martin G and Lo Coco F. Choice of chemotherapy in induction,consolidation and maintenance in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003: 16(3): 443–451.CrossRefGoogle Scholar
  46. Avvisati G, Petti MC, Lo Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mendelli F, GIMEMA Italian Coopertive Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukaemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimum follow-up. Blood 2002; 100: 3141–6.Google Scholar
  47. Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huget F, Vekhoff A, Meyer-Monard S, Maloisei F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P, European Acute Promyelocytic Group. Is cytarabine useful in the treatment of acute promyelocytic leukaemia? Results of a randomized trial from the European Acute Promyelocytic Leukaemia Group. J Clin Oncol 2006; 24(36): 5703–5710.PubMedCrossRefGoogle Scholar
  48. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sans M, Link H, Maloisel F, Gardin C, Bordessoule D, Stoppa AM, Sadoun A, Muus P, Wandt H, Mineur P, Whittaker JA, Fey M, Daniel MT, Castaigne S, Degos L. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukaemia. European APL Group. Leukaemia 2000; 14; 1371–1377.CrossRefGoogle Scholar
  49. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM & Wiernik PH All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997; 337: 1021–1028.PubMedCrossRefGoogle Scholar
  50. Kanamaru A, Takemoto Y, Tanimoto M, Marakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Shakamaki H, Tsubaki K. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukaemia Blood 1995: 85:1202–1206.PubMedGoogle Scholar
  51. Burnett A.K., Grimwade D, Solomon E, Wheatley K, Goldstone A.H on behalf of the MRC adult leukaemia working party Presenting white cell blood count and kinetics of molecular remission predict prognosis in acute promyelocytic leukaemia treated with all-trans retinoic acid: result of the randomised MRC trial. Blood 1999; 93, 4131–4143.PubMedGoogle Scholar
  52. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Concetta Petti, M, Rodeghiero F, Sagilo G, Luce Vegna M, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, and Lo Coco F. for the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto and Associazione Italiana di Ematologica ed Oncologia Pediatrica Cooperative groups Molecular remission in PML/RARAa positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90:1014–1021.PubMedGoogle Scholar
  53. Tallman MS, Nabhan CH, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759–767.PubMedCrossRefGoogle Scholar
  54. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzalez JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, and Deben G for the PETHEMA Group. A modified AIDA protocol with anthracycline-based consolidation results in high anti leukemic efficacy and reduced toxicity in newly diagnosed PML/RARα -positive acute promyelocytic leukemia. Blood 1999; 94:3015–3021.Google Scholar
  55. Falanga A, & Rickles FR Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukemia. Best Practice & Research Clinical Hematology 2003; 16: 463–482.CrossRefGoogle Scholar
  56. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ & Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572.PubMedGoogle Scholar
  57. Chomienne C, Ballerini P, Balitrans N, Daniel MT, Fenaux P, Castaigne S, Degos L. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990; 76: 1710–1717.PubMedGoogle Scholar
  58. Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, Kwaan HC, Peitta E & Rickles FR Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. Journal of Thrombosis and Haemostatis 2004, 2, 1341–1350.CrossRefGoogle Scholar
  59. Tallman MS, Brenner B, Serna Jde L, Dombret H, Falanga A, Kwaan HC, Liebman H, Raffoux E, Rickles FR. promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005; 29: 347–351.Google Scholar
  60. Milligan DW, Grimwade D, Cullis J O, Bond L, Swirsky D, Craddock C, Kell J, Homewood J, Campbell K, McGinley S, Wheatley K, Jackson G. Guidelines on the management of acute myeloid leukemia in adults. British Committee for Standards in Haematology (BCSH). Br J Haematol 2006; 135(4):450–474.PubMedCrossRefGoogle Scholar
  61. Sanz MA, Tallman MS & Lo Coco F. The tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019–3025.PubMedCrossRefGoogle Scholar
  62. Vahdat L, Maslak P, Miller WH, Eardkey A, Heller G, Scheinberg DA, Warrell RP. Early mortality and the retinoic acid syndrome in acute promyelocytic leukaemia: impact of leucocytosis, low – dose chemotherapy, PML-RAR(alpha) isoform, and CD 13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843–3849.PubMedGoogle Scholar
  63. Frankel S.R, Eardley A, Lauwers G, Weiss M, Warrell R.P. The “retinoic acid syndrome” in acute promyelocytic leukaemia. Annals of Internal Medicine 1992; 117: 292–296.PubMedGoogle Scholar
  64. De Botton S, Dombret H, Sanz M, San Miguel J, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Gelser K, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P and the European APL Group. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998; 92: 2712–2718.Google Scholar
  65. de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J, Calliot D, Vekhoff A, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Fey M, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Degos L, Fenaux P, European APL group. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukaemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 2003; 17 (2): 339–342.PubMedCrossRefGoogle Scholar
  66. Firkin F, Matthews J, Bradstock K & Wiley JS A phase II study of all-trans retinoic acid (ATRA) with Prednisolone prophylaxis in the treatment of acute promyelocytic leukemia (APL). Blood 1999; 94 (Suppl. 2): 228B (abstract).Google Scholar
  67. Wiley JS & Firkin FC. Reduction of pulmonary toxicity by Prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995; 9: 774–778.PubMedGoogle Scholar
  68. Mahmoud HH, Hurwitz CA, Roberts WM, Santana VM, Ribeiro RC, Krance RA. Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet 1993; 342: 1394–1395.PubMedCrossRefGoogle Scholar
  69. Castaigne S, Lefebvre P, Chomienne C, Suc E, Rigal-Huguet F, Gardin C, Delmer A, Archimbaud E, Tilly H, Janvier M, Isnard F, Travade P, Montfort L, Delannoy A, Rapp MJ, Christian B, Montastruc M, Weh Hans, Fenaux P, Dombret H, Gourmel B and Degos L. Effectiveness and pharmacokinetics of low –dose all-trans retinoic acid (25mg/m2) in acute promyelocytic leukaemia. Blood 1993; 82: 3560–3563.PubMedGoogle Scholar
  70. Warrell R.P. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood 1993; 82: 1949–1953.PubMedGoogle Scholar
  71. Ding W, Li Y.-P., Nobile L.M. Grills G, Carrera I. Paietta E, Tallman M.S, Wiernik P.H., Gallagher R.E. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RAR alpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172–1183.PubMedGoogle Scholar
  72. Gupta V, Yi QL, Branwein J, Lipton JH, Messner HA, Schuch AC, Wells RA, Minden MD. Role of all-trans retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res 2005; 29(1): 113–114.PubMedCrossRefGoogle Scholar
  73. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, de la Serna J, Roman J, Barragan E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, and Bolufer P. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood 2004; 103:1237–1243.PubMedCrossRefGoogle Scholar
  74. Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle Y, Fuentes F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Brenner A, Zick L, Döhner K, Fröhling S, Döhner H, AML Study Group.High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukaemia. Leukemia 2005; 19( 6): 978–983. PubMedCrossRefGoogle Scholar
  75. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, Diaz-Mediavilla, Fioritoni G, Gonález J D,Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonalez M, Rodeghiero F, Colomer D, Petti M C, Ribera JM, Mandelli F for the Spanish PETHEMA and the Italian GIMEMA Cooperative Groups. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promylecytic leukaemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96(4): 1247–1253.Google Scholar
  76. Lo-Coco F, Avvisati G, Vignetti M. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group. Blood 2004; 104:392a.CrossRefGoogle Scholar
  77. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Sagilio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A & Lo Coco F. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR[alpha] fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. Blood 1998; 92: 784–789.PubMedGoogle Scholar
  78. Avvisati G, Petti MC, Lo Coco F, Testi AM, Fazi P, Specchia G, Malagola M, Di Bona E, Recchia A, Marmont F, Buelli M, Lazzarino M, Di Raimondo F, Leoni F, Kropp MG, Vineri D, Miccolis I, Rossi G, Venditti A & Mandelli F AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood 2003; 102 (Suppl. 1): 487 (abstract).Google Scholar
  79. Lo-Coco F, Ammatuna E.The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment.Hematology Am Soc Hematol Educ Program. 2006:156–61, 514. Review.Google Scholar
  80. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.PubMedGoogle Scholar
  81. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102:2746–2755.PubMedCrossRefGoogle Scholar
  82. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318–2357. Review.PubMedCrossRefGoogle Scholar
  83. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT- PCR analysis of PMLRAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101:2521–2528.PubMedCrossRefGoogle Scholar
  84. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G. The value of allogeneic bone marrow transplant on patients with acute myeloid leukaemia at differing risk of relapse; results of the UK MRC AML 10 trial. British Journal of Haematology 2002: 118: 385-400.PubMedCrossRefGoogle Scholar
  85. Burnett A.K, Goldstone A.H., Stevens R.M.F., Hann I.M., Rees J.K.H. Gray R.G.,Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute promyelocytic leukaemia in first remission – results of MRC AML 10-trial. Lancet 1998; 351: 700–708.PubMedCrossRefGoogle Scholar
  86. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.PubMedGoogle Scholar
  87. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States Multicenter Study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.PubMedGoogle Scholar
  88. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukaemia. Proc Natl Acad Sci USA 2004; 101: 5328–5335.PubMedCrossRefGoogle Scholar
  89. Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J, Sigal L, Bendirdjian E. Retinoid/arsenic combination therapy of promyelocytic leukaemia: induction of telomerase-dependent cell death. Leukemia 2005; 19(10):1806–1811.PubMedCrossRefGoogle Scholar
  90. George B,Mathews V, Poonkuzhali B, Shaji RV, Srivastava A,Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single centre experience. Leukemia 2004; 18(10): 1587–1590.PubMedCrossRefGoogle Scholar
  91. Powell BL. Effect of consolidation with arsenic troxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukaemia (APL): North American Intergroup Protocol C9710. Journal of Clinical Oncology 2007; 25(18S): 2Google Scholar
  92. Sanz MA, Fenaux P, Lo Coco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231–1235.PubMedGoogle Scholar
  93. Tallman MS. Treatment of relapsed refractory acute promyelocytic leukemia. Best Pract res Clin Haematol 2007; 20: 57–65.PubMedCrossRefGoogle Scholar
  94. de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P; European APL Group; PETHEMA Group. Extramedullary relapse in acute Promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006; 20: 35–41.Google Scholar
  95. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F, Di Raimondo F, Martino B, Ferrara F, Selleri C, Liso V, Mandelli F. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell’Adulto. J Clin Oncol 2001; 19: 4023–4028.PubMedGoogle Scholar
  96. Breccia M, Carmosino I, Diverio D, De Santis S, De Propris MS, Romano A, Petti MC, Mandelli F, Lo-Coco F. Early detection of meningeal localization in acute promyelocytic leukemia patients with high presenting leucocyte count. British J Haematol 2003; 120: 266–270.CrossRefGoogle Scholar
  97. Lo Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16: 503–520.PubMedCrossRefGoogle Scholar
  98. Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M, Lazzarino M, Bernasconi C. Management of acute promyelocytic leukemia relapse in the ATRA era. Haematologica 1998; 83: 714–717.PubMedGoogle Scholar
  99. Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, González San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA; the Spanish Cooperative Group PETHEMA. Outcome of patients with acute Promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007; 21: 446–452.Google Scholar
  100. Lo Coco F, Ammatuna E, Sanz MA. Current treatment of acute promyelocytic leukemia. Haematologica 2007; 92: 289–290.PubMedCrossRefGoogle Scholar
  101. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131–134.PubMedCrossRefGoogle Scholar
  102. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H.Combined tretament with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute Promyelocytic leukemia. J Clin Oncol 2003; 21: 2326–2334.PubMedCrossRefGoogle Scholar
  103. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F.Gentuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute Promyelocytic leukemia. Blood 2004; 104: 1995–1999.PubMedCrossRefGoogle Scholar
  104. Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigeno K, Horii T, Shirai N, Maekawa M, Ohnishi K, Naoe T, Ohno R.Efficacy of gentuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19: 1306–1311.PubMedCrossRefGoogle Scholar
  105. Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M.Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARα-positive leukemic cells. Haematologica 2007; 92: 324–331.CrossRefGoogle Scholar
  106. Sanz MA, Labopin M, Gorin NC, de la Rubia J, Arcese W, Meloni G, Bacigalupo A, Alessandrino P, Carreras E, Iriondo A, Novitzky N, Jacobs P, Bandini G, Lo-Coco F, Frassoni F, Rocha V; Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 2007; 39: 461–469.PubMedCrossRefGoogle Scholar
  107. Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U.Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res. 2007;31(11):1585–1587. Epub 2007 Apr 9.PubMedCrossRefGoogle Scholar
  108. Arrigoni P, Beretta C, Silvestri D, Rossi V, Rizzari C, Valsecchi MG, Cazzaniga G, Biondi A. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. Brit J Haematol. 2003;120(1):89–92.CrossRefGoogle Scholar
  109. Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ES, Chan CH, Wong KF, Kwong YL. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Brit J Haematol 2004; 125: 463–469.CrossRefGoogle Scholar
  110. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O’Farrell AM, Gilliland DG, Le Beau MM, Kogan SC. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SUII657. Blood 2003; 101: 3188–3197.PubMedCrossRefGoogle Scholar
  111. Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH Jr, Lo Coco F, Pelicci PG, Nervi C. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene 2005; 24: 1820–1830.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Andrea Biondi
    • 1
  • Anna Maria Testi
  • Brenda E. S. Gibson
  1. 1.Centro M. Tettamanti, Clinica Pediatrica Università Milano-Bicocca, Ospedale San GerardoMonzaItaly

Personalised recommendations